Refractory Acute Biphenotypic Leukemia: Clinical Trials

2 trials for Refractory Acute Biphenotypic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Terminated 1
Phase 11Terminated 1

Follow Refractory Acute Biphenotypic Leukemia: new trials by email Literature Review of Refractory Acute Biphenotypic Leukemia trials Research Report on Refractory Acute Biphenotypic Leukemia

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center242021-12-172025-11-03
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Decitabine and Cedazuridine, Venetoclax - Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia
Phase 2Active not recruitingM.D. Anderson Cancer Center202021-09-292026-11-12

Narrower conditions

Leukemia, Biphenotypic, Acute (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Hematologic Neoplasms (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia (2)  ·  Leukemia, Lymphoid (2)  ·  Leukemia, Myeloid (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Bone Marrow Diseases (1)  ·  Neoplasms by Site (1)

Interventions

venetoclax (2)  ·  Esters (1)  ·  Homoharringtonine (1)  ·  decitabine and cedazuridine drug combination (1)

Sponsors

M.D. Anderson Cancer Center (2)

Countries

United States (2)

Top investigators

Abhishek Maiti (1)  ·  Courtney DiNardo, MD (1)

Results publications

PMID 40979071